Corbus Pharmaceuticals Holdings Inc (CRBP) - News Archive

Differentiating Efficacy: Expanded Clinical Insights on CRB-701 in Head and Neck and Cervical Cancers Corbus Pharmaceuticals has captured significant attention in the oncology landscape with the presentation of promisin...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a biopharmaceutical company focused on developing innovative therapies in oncology and obesity, recently made significant announcements concerning its robust researc...

Corbus Pharmaceuticals Advances in Oncology with CRB-701 NORWOOD, Mass. Oct. 16, 2024 In a significant milestone for cancer therapeutics, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has completed enrollment for...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) has been gaining significant attention in the stock market, with its shares outperforming competitors and showing promising results. This has prompted B. Riley Securiti...

Corbus Pharmaceuticals Holdings Inc (CRBP) is a renowned biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet medical needs. The company has recently garnered at...

CRB-701 (SYS6002): Promising Results in Targeting Nectin-4 Positive TumorsCorbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results for their next-generation antibody drug conj...

The pharmaceutical industry is abuzz with the exciting news of Corbus Pharmaceuticals Holdings, Inc. releasing updated Phase 1 clinical data for their revolutionary drug, SYS-6002 (CRB-701). This groundbreaking advance...

NORWOOD, Mass., Jan. 31, 2024 - Corbus Pharmaceuticals Holdings Inc. has proven its prowess in the precision oncology industry once again with the successful pricing of its underwritten public offering. The company, lis...

Corbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results from the first-in-human clinical study of their investigational drug, CRB-701 (SYS6002), presented at the 2024 America...

Corbus Pharmaceuticals Holdings, Inc., a progressive biopharmaceutical company, announced the release of the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (also known as CRB-701). The abstract...

In the field of cancer therapeutics, precision oncology approaches have gained significant attention due to their promise in delivering personalized treatments with improved efficacy. Corbus Pharmaceuticals Holdings, In...

NORWOOD, Mass., Dec. 18, 2023 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently made a significant announcement that holds tremendous potential for advancing precision oncology. The company disclosed t...